miR-101 and EZH2 in Glioblastoma
Author Information
Author(s): Smits Michiel, Nilsson Jonas, Mir Shahryar E., van der Stoop Petra M., Hulleman Esther, Niers Johanna M., de Witt Hamer Phillip C., Marquez Victor E., Cloos Jacqueline, Krichevsky Anna M., Noske David P., Tannous Bakhos A., Würdinger Thomas
Primary Institution: Cancer Center Amsterdam, VU University Medical Center
Hypothesis
miR-101 is down-regulated in glioblastoma, leading to increased EZH2 expression and tumor progression.
Conclusion
Inhibition of EZH2 may be a potential therapeutic strategy to target glioblastoma proliferation, migration, and angiogenesis.
Supporting Evidence
- miR-101 is down-regulated in glioblastoma cells.
- Inhibition of EZH2 reduced glioblastoma cell growth and migration.
- EZH2 overexpression correlates with poor patient survival.
- In vivo studies showed reduced tumor growth with EZH2 inhibition.
Takeaway
This study found that a small molecule called miR-101 is not working properly in brain tumors, which makes another protein, EZH2, too active and helps the tumor grow.
Methodology
The study involved in vitro and in vivo experiments to assess the effects of miR-101 and EZH2 on glioblastoma cell growth, migration, and angiogenesis.
Limitations
The study primarily focused on a specific miRNA and its target without exploring other potential regulatory mechanisms.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website